---
title: "Swimming downstream: statistical analysis of differential transcript usage following Salmon quantification"
author:
- name: Michael I. Love
  affiliation: 
  - Department of Biostatistics, UNC-Chapel Hill, Chapel Hill, NC, US
  - Department of Genetics, UNC-Chapel Hill, Chapel Hill, NC, US
- name: Charlotte Soneson
  affiliation:
  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland
  - SIB Swiss Institute of Bioinformatics, Zurich, Switzerland
- name: Rob Patro
  affiliation: Department of Computer Science, Stony Brook University
date: 5 June, 2018
vignette: >
  %\VignetteIndexEntry{RNA-seq workflow for differential transcript usage following Salmon quantification}
  %\VignetteEngine{knitr::rmarkdown}
abstract: |
  RNA-seq workflow for differential transcript usage following Salmon quantification.
keywords: RNA-seq, workflow, differential transcript usage, Salmon, DRIMSeq, DEXSeq, stageR, tximport
bibliography: bibliography.bib
output: BiocWorkflowTools::f1000_article
---

<!-- to compile this: 
  rmarkdown::render("rnaseqDTU.Rmd")
-->

<!-- a list of all required libraries:
  reqlibs = sub(".*library\\((.*?)\\).*","\\1",grep("library\\(",readLines("rnaseqDTU.Rmd"),value=TRUE))
  find.package(reqlibs)
-->

```{r style, echo=FALSE, message=FALSE, warning=FALSE, results="asis"}
library(knitr)
library(rmarkdown)
opts_chunk$set(message=TRUE, warning=FALSE, error=FALSE, 
               cache=TRUE, fig.width=5, fig.height=5)
```

**R version**: `r R.version.string`

**Bioconductor version**: `r BiocInstaller::biocVersion()`

<!-- fix this to rnaseqDTU later -->
**Package**: `r packageVersion("DRIMSeq")`

# Introduction

RNA-seq experiments can be analyzed to detect differences across groups of
samples in total gene expression -- the total expression 
produced by all isoforms of a gene -- and additionally differences in
transcript usage within a gene. If the amount of expression
switches among two or more isoforms of a gene, then the total gene
expression may not change by a detectable amount, but such
differential transcript usage is still of interest to biological and
biomedical researchers. While many tutorials and workflows in the
Bioconductor project address differential gene expression, there are
fewer workflows for performing a differential transcript usage analysis,
which provides critical and complementary information to a 
gene-level analysis. Some of the existing Bioconductor packages and vignettes that 
can be used to detect differential transcript usage include *BitSeq*, 
*DEXSeq* (originally designed for differential exon usage), `diffSpliceDGE` 
from the *edgeR* package, `diffSplice` from the *limma* package, *DRIMSeq*, 
*stageR*, and *IsoformSwitchAnalyzeR* (cite). 
Others can be found at the following link: 
<https://bioconductor.org/packages/release/BiocViews.html#___DifferentialSplicing>.
For more information about the Bioconductor project and its core
infrastructure, please refer to the (cite latest Bioc paper).

We note that there are numerous other methods for detecting
differential transcript usage outside of the Bioconductor project. The
*DRIMSeq* publication (cite) is a good reference and has descriptions and
comparisons with many such methods.
This workflow will build on the methods and vignettes from three
Bioconductor packages: *DRIMSeq*, *DEXSeq*, and *stageR*.

Previously, some of the developers of the Bioconductor packages 
*edgeR* and *DESeq2* (cite) have collaborated to develop the
*tximport* package (cite) for summarizing the output of fast
transcript-level quantifiers, such as *Salmon* [@Patro2017Salmon],
*Sailfish*, and *kallisto* (cite). The *tximport* package focuses on
preparing estimated transcript-level counts, abundances
and effective transcript lengths, for gene-level statistical analysis
using *edgeR*, *DESeq2* or *limma-voom* (cite). *tximport* produces an
offset matrix to accompany gene-level counts, that accounts for
various RNA-seq biases (cite Salmon) as well as differences in
transcript usage among transcripts of different length that would bias
an estimator of fold change based on the gene-level counts (cite
Trapnell). *tximport* can alternatively produce a matrix of data that
is roughly on the scale of counts, by scaling TPM abundances to add up to
the total number of reads. This counts-from-abundance approach
directly corrects for technical biases and differential transcript
usage across samples, obviating the need for the accompanying offset matrix.

Complementary to an analysis of differential gene expression, one can
use *tximport* to import transcript-level estimated counts, and then pass these
counts to packages such as *DRIMSeq* or *DEXSeq* for statistical
analysis of differential transcript usage. Following a
transcript-level analysis, one can aggregate evidence of differential
transcript usage to the gene-level. The *stageR* package in
Bioconductor provides a statistical framework to *screen* at the
gene-level for differential transcript usage with gene-level adjusted p-values,
followed by *confirmation* of which transcripts within the significant
genes show differential usage with transcript-level adjusted p-values
(cite). The method provides _overall false discovery rate_ error
control for such a two-stage 
procedure, which will be discussed in more detail later in the
workflow. We believe that *stageR* represents a principled approach to
analyzing transcript usage changes, as the methods can be evaluated
against a target error rate in a manner that mimics how the methods
will actually be used in practice. That is, following rejection of
the null hypothesis at the gene-level, investigators would likely
desire to know which transcripts within a gene participated in the
differential usage.

Here we provide a basic workflow for detecting
differential transcript usage using Bioconductor packages,
following quantification of transcript abundance using the *Salmon*
method. This workflow includes live, runnable code chunks for analysis
using *DRIMSeq* and *DEXSeq*, as well as for performing stage-wise
testing of differential transcript usage using the *stageR*
package. For the workflow, we use data which is simulated, so that 
we can also evaluate the performance of methods for differential
transcript usage, as well as differential gene and transcript
expression. The simulation was constructed using experimental
parameters estimated from the GEUVADIS dataset (cite), including the
expression levels of the transcripts, the amount of biological
variability of expression levels across samples, and realistic coverage
of reads along the transcript.

# Methods

## Simulation

First we describe details of the simulated data, which will be used in
the following workflow. Understanding the details of the
simulation will be useful for assessing the methods in the later sections.
All of the code used to simulate RNA-seq experiments and write
paired-end reads can be found at the following
link: <https://github.com/mikelove/swimdown>. 
*Salmon* was used to estimate transcript-level abundances for a single
sample (ERR188297) of the GEUVADIS project (cite GEUVADIS, Salmon), and this was used as
a baseline for transcript abundances in the simulation. Transcripts
which were associated with estimated counts less than 10 had abundance
thresholded to 0, all other transcripts were considered "expressed".
*alpine* was used to estimate realistic fragment GC bias from 12 samples from the GEUVADIS
project from the same center [@Love2016Alpine]. *DESeq2* was
used to estimate mean and dispersion parameters for a Negative
Binomial distribution for gene-level counts for 462 GEUVADIS samples
provided by the *recount2* project (cite DESeq2, recount2).
Note that, while gene-level dispersion estimates were used
to generate underlying transcript-level counts, additional uncertainty
on the transcript-level data is a natural consequence of the
simulation, as the transcript-level counts must be estimated (the
underlying transcript counts are not provided to the methods).

*polyester* was used to simulate paired-end RNA-seq reads for two
groups of 12 samples each, with realistic fragment GC bias, and with
dispersion on transcript-level counts following the joint distribution
of mean and dispersion values estimated from the GEUVADIS samples (cite). 
The first sample for group 1 and the first sample for group 2 followed the
realistic GC bias profile of the same sample, and so on for all 12
samples. This pairing of the samples was used to generate balanced
data, but not used in the statistical analysis. 
*countsimQC* was used to
examine the properties of the simulation relative to the dataset used
for parameter estimation, and the full report can be accessed at the
following link: <https://github.com/mikelove/swimdown/countsimqc>
(cite countsimqc).

Differential expression across two groups was generated as follows:
70% of the genes were set as "null genes", where abundance was not
changed across the two groups. For 10% of genes, all isoforms were
differentially expressed at a log fold change between 1 and 2.58. This
set of genes and transcripts were classified as "DGE" (differential
gene expression) but did not count as "DTU" (differential transcript
usage). To simulate balanced differential expression, one of
the two groups was randomly chosen to be the baseline, and the other group
would have its counts multiplied by the fold change. For 10% of genes,
a single expressed isoform was differentially expressed at a log fold
change between 1 and 2.58. This set of genes was termed "DTE" (
differential transcript expression). If the chosen transcript was the
only expressed isoform of a gene, this counted as DGE and not DTU,
but if there were other isoforms which are expressed, such genes
counted for both DGE and DTU, as the proportion of expression among
the isoforms was affected. For 10% of genes, differential transcript
usage was constructed by exchanging the abundance of two expressed
isoforms, or, if only one isoform was expressed, exchanging the
abundance of the expressed isoform with a non-expressed one. Such
genes counted for DTU, but not for DGE. An MA plot of the simulated
abundances for the two groups is shown in Figure
\@ref(fig:ma-simulated).

```{r ma-simulated, message=FALSE, echo=FALSE, dev="png", out.width="50%", fig.cap="MA plot of simulated abundances. Each point depicts a transcript, with the average of log2 abundance (TPM) on the x-axis and the difference between the two groups on the y-axis. Of the transcripts which were expressed with TPM > 1 in at least one group, 77\\% are null transcripts (grey), which fall by construction on the M=0 line, and 23\\% are differentially expressed (green, orange, or purple)."}
load("simulate.rda")
library(rafalib)
bigpar()
pc <- 1
col <- rep(8, nrow(tpms))
col[iso.dge] <- 1
col[iso.dte] <- 2
col[iso.dtu] <- 3
maplot(log2(tpms[,1]+pc), log2(tpms[,2]+pc),
       n=nrow(tpms), curve.add=FALSE,
       col=col, cex=.25, pch=20)
legend("bottomright",
       c("DGE","DTE","DTU","null"),
       col=c(1:3,8), pch=20, bty="n")
```

## Operation

This workflow was designed to work with R 3.5 or higher, and the
*DRIMSeq*, *DEXSeq*, *stageR* and *tximport* packages for Bioconductor
version 3.7 or higher. Bioconductor packages should always be
installed following the [official instructions](https://bioconductor.org/install).
The workflow uses a subset of all genes to speed
up the analysis, but the Bioconductor packages can easily be run for
this dataset on all human genes on a laptop in less than an
hour. Timing for the various packages is included within each section.

# Quantification and data import

## Salmon quantification

We used *Salmon* version 0.10.0 to quantify abundance and effective
lengths for all of the 24 simulated samples. For this workflow, we
will use the first six samples from each group. We quantified against
the [GENCODE](https://www.gencodegenes.org/releases/current.html)
human annotation version 28, which was the same reference used to
generate the simulated reads. We used the transcript sequences FASTA
file which contains "Nucleotide sequences of all transcripts on the
reference chromosomes". When downloading the FASTA file, it is useful
to download the corresponding GTF file, as this will be used in later
sections. 

To build the *Salmon* index, we used the following command:

```
salmon index -t gencode.v28.transcripts.fa -i gencode.v28_salmon-0.10.0
```

To quantify each sample, we used the following command, which uses 6
threads, and performs fragment GC bias modeling. The library type is
specified by `-l IU` and is discussed at this link:
<http://salmon.readthedocs.io/en/latest/library_type.html>. Recent 
versions of Salmon can automatically detect the library type by
setting `-l A`. Such a command can be automated in a bash loop using
bash variables, or one can use more advanced workflow management
systems such as Snakemake [@Koster2012Snakemake] or Nextflow [@Di2017Nextflow].

```
salmon quant -p 6 -i gencode.v28_salmon-0.10.0 -l IU \
      --gcBias -o sample -1 sample_1.fa.gz -2 sample_2.fa.gz
```

## Importing counts into R/Bioconductor

We can use *tximport* to import the estimated counts, abundances and
effective transcript lengths into R. We recommend to keep a CSV file
that keeps track of the sample identifiers and any relevant variables,
e.g. condition, time point, batch, and so on. Here we have made a
sample CSV file which records which sample is condition 1 and which is
condition 2. The columns of this CSV can have any names, although
`sample_id` will be used later by *DRIMSeq*, and so using this column
name allows us to pass this *data.frame* directly to *DRIMSeq* at a
later step.

```{r}
samps <- read.csv("samples.csv")
head(samps)
samps$condition <- factor(samps$condition)
table(samps$condition)
files <- file.path("/path/to/dir", samps$sample_id, "quant.sf")
names(files) <- samps$sample_id
head(files)
```

We can then import transcript-level counts using *tximport*.
We suggest to generate counts from abundance, using the
`scaledTPM` method described by Soneson et al (cite). As described
above, the `countsFromAbundance` option of *tximport* uses estimated
abundances to generate roughly count-scaled data, such that each
column will sum to the number of reads mapped for that library. 
We recommend `scaledTPM` for differential transcript usage
so that the estimated proportions fit by *DRIMSeq* in
following sections correspond to the proportions of underlying
abundance. 

If instead of `scaledTPM`, we used the original estimated transcript counts
(`countsFromAbundance="no"`), or if we used `lengthScaledTPM`
transcript counts, then a change in transcript usage among
transcripts of different length could result in a changed total count
for the gene, even if there is no change in total gene
expression. This is because the original transcript counts and
`lengthScaledTPM` transcript counts are proportional to transcript
length, while `scaledTPM` transcript counts are not. For testing DTU
using *DRIMSeq* and *DEXSeq*, it is convenient if the count-scale data
is *not* proportional to transcript length within a gene.
Note that this could be corrected by an offset, but this is not
easily implemented in the current packages. While this workflow only
considers existing software features, we are considering developing a new
`countsFromAbundance` method which would scale abundance for all
transcripts of a gene by a fixed gene length, then each sample by its
number of mapped reads, therefore balancing between the benefits of
`scaledTPM` and `lengthScaledTPM`.

The following code chunk is not evaluated, but instead we will load a
pre-constructed matrix of counts. The actual quantification files for
this dataset have been made publicly available, see the *Data
availability* section at the end of this workflow.

```{r eval=FALSE}
library(tximport)
txi <- tximport(files, type="salmon", txOut=TRUE,
                countsFromAbundance="scaledTPM")
cts <- txi$counts
cts <- cts[rowSums(cts) > 0,]
```

## Transcript-to-gene mapping

Bioconductor offers numerous approaches for building a *TxDb* object,
a transcript database that can be used to link transcripts to genes.
We used the following unevaluated code chunks to generate a *TxDb*,
used the `select` function with the *TxDb* to produce 
a corresponding *data.frame* called `txdf` which links transcript IDs
to gene IDs (in this *TxDb* the transcript IDs are called `TXNAME` and
the gene IDs are called `GENEID`). The version 28 human GTF file was
downloaded from the GENCODE website when we downloaded the transcripts
FASTA file. 

```{r eval=FALSE}
library(GenomicFeatures)
gtf <- "gencode.v28.annotation.gtf.gz"
txdb.filename <- "gencode.v28.annotation.sqlite"
txdb <- makeTxDbFromGFF(gtf)
saveDb(txdb, txdb.filename)
```

Once the *TxDb* database has been saved, it can be quickly reloaded:

```{r eval=FALSE}
txdb <- loadDb(txdb.filename)
txdf <- select(txdb, keys(txdb, "GENEID"), "TXNAME", "GENEID")
tab <- table(txdf$GENEID)
txdf$ntx <- tab[match(txdf$GENEID, names(tab))]
```

# Statistical analysis of differential transcript usage

## DRIMSeq

We load the `cts` object as created in the code chunk above. This
contains count-scale data, generated from abundance using the
`scaledTPM` method. The column sums are equal to the number of mapped 
paired-end reads per experiment. The experiments have between 31 and
38 million paired-end reads that were mapped to the transcriptome
using *Salmon*.

```{r}
load("salmon_cts.rda")
cts[1:3,1:3]
range(colSums(cts)/1e6)
```

We also have the `txdf` object giving the transcript-to-gene
mappings (for construction, see previous section). 
This is contained in a file called `simulate.rda` that
contains a number of R objects with information about the
simulation, that we will use later to assess the methods'
performance. 

```{r}
load("simulate.rda")
head(txdf)
all(rownames(cts) %in% txdf$TXNAME)
txdf <- txdf[match(rownames(cts),txdf$TXNAME),]
all(rownames(cts) == txdf$TXNAME)
```

In order to run *DRIMSeq*, we build a *data.frame* with the gene ID,
the feature (transcript) ID, and then columns for each of the samples:

```{r}
counts <- data.frame(gene_id=txdf$GENEID,
                     feature_id=txdf$TXNAME,
                     cts)
```

We can now load the DRIMSeq package and create a *dmDSdata* object,
with our `counts` and `samps` *data.frames*. Typing in the object name
and pressing return will give information about the number of genes:

```{r}
library(DRIMSeq)
d <- dmDSdata(counts=counts, samples=samps)
d
```

The *dmDSdata* object has a number of specific methods. Note that the
rows of the object are gene-oriented, so pulling out the first *row*
corresponds to all of the transcripts of the first gene:

```{r}
methods(class=class(d))
counts(d[1,])[,1:4]
```

It will be useful to first filter the object, before running
procedures to estimate model parameters. This greatly speeds up the
fitting and removes transcripts which would be troublesome for
parameter estimation, e.g. estimating the proportion of expression
among the transcripts of a gene when the total count is very low. We first
define `n` to be the total number of samples, and `n.small` to be the
sample size of the smallest group. We use all
three of the possible filters: we require that (1) at least `n.small`
samples have a count of 10, for a transcript to be included in the
dataset, (2) at least `n.small` samples have a proportion of 0.1 or
larger, and (3) that all `n` samples have a total count of 10 or
more. 

It is important to consider what types of transcripts may be removed
by the filters, and potentially adjust depending on the dataset.  If
`n` was large, it would make sense to allow perhaps a few samples to
have very low counts, so lowering `min_samps_gene_expr` to some
multiple $< 1$ of `n`, and likewise for the first two filters for
`n.small`. The second filter means that if a transcript does not make
up more than 10% of the gene's expression for at least `n.small`
samples, it will be removed. If this proportion seems to high, for
example, if very lowly expressed isoforms are of particular interest,
then the filter can be omitted or the `min_feature_prop`
lowered. After filtering, this dataset has 7,764 genes.

```{r}
n <- 12
n.small <- 6
d <- dmFilter(d,
              min_samps_feature_expr=n.small, min_feature_expr=10,
              min_samps_feature_prop=n.small, min_feature_prop=0.1,
              min_samps_gene_expr=n, min_gene_expr=10)
d
```

The following plot gives a useful overview (Figure
\@ref(fig:data-hist)). We can see the numbers driving the histogram
by tabulating the number of times we see a gene ID, then tabulating
the output again.

```{r data-hist, out.width="50%", fig.cap="Histogram of the number of genes by number of transcipts."}
plotData(d)
table(table(counts(d)$gene_id))
```

We create a design matrix, using a design formula and the sample
information contained in the object, accessed via *samples*. Here we
use a simple design with just two groups, but more complex designs are
possible. For some discussion of complex designs, one can refer to
the vignettes of the *limma*, *edgeR*, or *DESeq2* packages.

```{r}
design_full <- model.matrix(~condition, data=DRIMSeq::samples(d))
colnames(design_full)
```

Only for speeding up the code evaluations in this workflow, we subset
to the first 250 genes, representing about one thirtieth of the
dataset. This step would not be run in a typical workflow.

```{r}
d <- d[1:250,]
7750 / 250
```

We then use the following three functions to estimate the model
parameters. We first estimate the *precision*, which is related to the
dispersion in the Negative Binomial via the formula below. Because
precision is in the denominator of the right hand side of the
equation, they are inversely related. Higher *dispersion* -- counts more
variable around their expected value -- is associated with lower
*precision*. For full details about the DRIMSeq model, one should read
both the DRIMSeq software vignette and the DRIMSeq publication
[@Nowicka2016DRIMSeq]. After estimating the precision, we fit regression coefficients
and perform null hypothesis testing on the coefficient of
interest. Because we have a simple two-group model, we test the
coefficient associated with the difference between condition 2 and
condition 1, called `condition2`. The following code takes about half
a minute, and so a full analysis on this dataset takes about 15
minutes on a laptop.

\[ \textrm{dispersion} = \frac{1}{1 + \textrm{precision}} \]

```{r}
set.seed(1)
system.time({
  d <- dmPrecision(d, design=design_full)
  d <- dmFit(d, design=design_full)
  d <- dmTest(d, coef="condition2")
})
```

To build a results table, we run the `results` function. We can
generate a single p-value per gene, which tests whether there is any
differential transcript usage, or a single p-value per transcript,
which tests whether the proportions for this transcript changed within
the gene:

```{r}
res <- DRIMSeq::results(d)
head(res)
res.txp <- DRIMSeq::results(d, level="feature")
head(res.txp)
```

Because the `pvalue` column may contain `NA` values, we use the
following function to turn these into 1's. The `NA` values would
otherwise cause problems for the stage-wise analysis.

```{r}
no.na <- function(x) ifelse(is.na(x), 1, x)
res$pvalue <- no.na(res$pvalue)
res.txp$pvalue <- no.na(res.txp$pvalue)
```

We can plot the estimated proportions for one of the significant
genes, where we can see evidence of switching (Figure \@ref(fig:plot-prop)).

```{r plot-prop, out.width="50%", fig.cap="Estimated proportions for one of the significant genes."}
idx <- which(res$adj_pvalue < 0.05)[1]
res[idx,]
plotProportions(d, res$gene_id[idx], "condition")
```

## stageR following DRIMSeq

Because we have been working with only a subset of the data, we now
load the results tables that would have been generated by running
*DRIMSeq* functions on the entire dataset.

```{r}
load("drim_tables.rda")
nrow(res)
nrow(res.txp)
```

A typical analysis of differential transcript usage would involve
asking first: "which genes contain any evidence of DTU?", and secondly
"which transcripts in the genes that contain some evidence may be
participating in the DTU?". Note that a gene may pass the first
stage without exhibiting enough evidence to identify one or more
transcripts that are participating. The *stageR* package is designed
to allow for such two-stage testing procedures, where the first stage
is called a *screening* stage and the second stage a *confirmation*
stage [@Van2017StageR]. The methods are general, and can also be applied to
testing, for example, changes across a time series followed by
investigation of individual timepoints, as shown in the *stageR*
package vignette. We show below how *stageR* is used to detect DTU and
how to interpret its output.

We first construct a vector of p-values for the screening
stage. Because of how the *stageR* package will combine transcript and
gene names, we need to strip the gene and transcript version numbers
from their Ensembl IDs (this is done by taking the first 15 characters).

```{r}
pScreen <- res$pvalue
strp <- function(x) substr(x,1,15)
names(pScreen) <- strp(res$gene_id)
```

We construct a one column matrix of the confirmation p-values:

```{r}
pConfirmation <- matrix(res.txp$pvalue, ncol=1)
rownames(pConfirmation) <- strp(res.txp$feature_id)
```

We arrange a two column *data.frame* with the transcript and gene
identifiers.

```{r}
tx2gene <- res.txp[, c("feature_id", "gene_id")]
for (i in 1:2) tx2gene[,i] <- strp(tx2gene[,i])
```

The following functions then perform the analysis. We must specify an
`alpha` which will the *overall false discovery rate* target for the
analysis, which will be defined below. Unlike typical adjusted p-values or
q-values, we cannot choose an arbitrary threshold later: after
specifying `alpha=0.05`, we need to use 5% as the target in downstream
steps. There are also convenience functions *getSignificantGenes* and
*getSignificantTx* which are shown in the *stageR* vignette.

```{r message=FALSE}
library(stageR)
stageRObj <- stageRTx(pScreen=pScreen, pConfirmation=pConfirmation,
                      pScreenAdjusted=FALSE, tx2gene=tx2gene)
stageRObj <- stageWiseAdjustment(object=stageRObj, method="dtu", alpha=0.05)
suppressWarnings({
  drim.padj <- getAdjustedPValues(stageRObj, order=FALSE,
                                  onlySignificantGenes=TRUE)
})
head(drim.padj)
```

The final table with adjusted p-values summarizes the information from
the two stage analysis. Only genes which passed the filter are
included in the table, so the table already represents *screened* genes. 
The transcripts with `transcript` less than 0.05 pass the
*confirmation* stage and have a target 5% *overall false
discovery rate*, or OFDR. This means that, in expectation, no more
than 5% of the genes that pass screening will either (1) not contain
any DTU, so be falsely screened genes, or (2) contain a transcript with a
transcript adjusted p-value less than 0.05 which does not participate
in DTU, so contain a falsely confirmed transcript. The *stageR*
procedure allows us to look at both the genes that passed the
screening stage and the transcripts with adjusted p-values less than 
our target `alpha`, and understand what kind of *overall* error rate
this procedure entails. This cannot be said for an arbitrary procedure
of looking at simple gene adjusted p-values and transcript adjusted
p-values, where the adjustment was performed independently.

## Post-hoc filtering on the standard deviation in proportions

We found that *DRIMSeq* was sensitive to detect DTU, but could exceed
its FDR bounds particularly on the transcript-level tests. We found
that a post-hoc, non-specific filtering of the *DRIMSeq* results table
improved the FDR control. We considered the standard deviation of the
per-sample proportions as a filtering statistic. This statistic does
not use the information about which samples belong to which condition
group. Excluding transcripts with small standard deviation of the
per-sample proportions brought the observed FDR closer to its nominal
target in the simulation considered here, as shown below.

```{r}
res.txp.filt <- DRIMSeq::results(d, level="feature")
getSampleProportions <- function(d) {
  cts <- as.matrix(subset(counts(d), select=-c(gene_id, feature_id)))
  gene.cts <- rowsum(cts, counts(d)$gene_id)
  total.cts <- gene.cts[match(counts(d)$gene_id, rownames(gene.cts)),]
  cts/total.cts
}
prop.d <- getSampleProportions(d)
res.txp.filt$prop.sd <- sqrt(rowVars(prop.d))
res.txp.filt$pvalue[res.txp.filt$prop.sd < .1] <- 1
res.txp.filt$adj_pvalue <- p.adjust(res.txp.filt$pvalue, method="BH")
```

## DEXSeq

The *DEXSeq* package was originally designed for detecting
differential exon usage (cite), but can also be adapted to run on estimated
transcript counts from Salmon, in order to detect DTU. This
usage of *DEXSeq* was evaluated by (cite Soneson isoform filtering) in a
publication discussing the benefits in terms of FDR control of
filtering lowly expressed transcripts for a transcript-level
analysis. As the usage is quite different than its intended usage, we
also benchmarked its performance here. We begin with the *DRIMSeq*
filtered object, as these filters are intuitive and useful for paring
down the analysis. 

The two factors of working on isoform counts rather than
individual exons and using the *DRIMSeq* filtering options
dramatically increase the speed of *DEXSeq*, compared to running an
exon-level analysis. Another advantage is that we can benefit from
the sophisticated bias models of *Salmon*, which account for dips in
coverage on alternative exons that can otherwise throw off estimates
of transcript abundance. A disadvantage over the exon-level analysis
is that we must know in advance all of the possible isoforms that can
be generated from a gene locus, all of which are assumed to be
contained in the annotation files.

We first load the DEXSeq package and then build a *DEXSeqDataSet* from
the data contained in the *dmDStest* object (the class of the
*DRIMSeq* object changes as the results are added). The design formula
of the *DEXSeqDataSet* here uses the language "exon" but this should
be read as "transcript" for our analysis. *DEXSeq* will test, after
accounting for total gene expression for this gene and for the
proportion of this transcript relative to the others, whether there is
a condition-specific difference in the transcript proportion relative
to the others. The testing of "this" vs "others" in *DEXSeq* enables
it to be much faster than its original published version, which
involved fitting coefficients for each exon within a gene (here it
would have been for each transcript within a gene).

```{r message=FALSE}
library(DEXSeq)
sample.data <- DRIMSeq::samples(d)
count.data <- round(as.matrix(counts(d)[,-c(1:2)]))
dxd <- DEXSeqDataSet(countData=count.data,
                     sampleData=sample.data,
                     design=~sample + exon + condition:exon,
                     featureID=counts(d)$feature_id,
                     groupID=counts(d)$gene_id)
```

The following functions run the *DEXSeq* analysis. While we are only
working on a subset of the data, the full analysis for this dataset
took less than 3 minutes on a laptop.

```{r}
system.time({
  dxd <- estimateSizeFactors(dxd)
  dxd <- estimateDispersions(dxd, quiet=TRUE)
  dxd <- nbinomLRT(dxd, reduced=~sample + exon)
})
```

We then extract the results table, not filtering on mean counts (as we
have already conducted filtering via *DRIMSeq* functions. We compute a
per-gene adjusted p-value, using the *perGeneQValue* function, which
aggregates evidence from multiple tests within a gene to a single
p-value for the gene and then corrects for multiple testing across
genes (cite DEXSeq). Other methods for aggregative evidence from the
multiple tests within genes have been discussed in a recent
publication and may be substituted at this step (cite Yi).
Finally, we build a simple results table with the
per-gene adjusted p-values.

```{r}
dxr <- DEXSeqResults(dxd, independentFiltering=FALSE)
qval <- perGeneQValue(dxr)
dxr.g <- data.frame(gene=names(qval),qval)
```

For size consideration, we reduce to a simple *data.frame* for the
transcript-level results table:

```{r}
columns <- c("featureID","groupID","pvalue")
dxr <- as.data.frame(dxr[,columns])
```

## stageR following DEXSeq

Again, as we have been working with only a subset of the data, we now
load the results tables that would have been generated by running
*DEXSeq* functions on the entire dataset.

```{r}
load("dex_tables.rda")
```

If the *stageR* package has not already been loaded, we make sure to
load it, and run code very similar to that used above for *DRIMSeq*
two stage testing, with a target `alpha=0.05`.

```{r}
library(stageR)
strp <- function(x) substr(x,1,15)
pConfirmation <- matrix(dxr$pvalue,ncol=1)
dimnames(pConfirmation) <- list(strp(dxr$featureID),"transcript")
pScreen <- qval
names(pScreen) <- strp(names(pScreen))
tx2gene <- as.data.frame(dxr[,c("featureID", "groupID")])
for (i in 1:2) tx2gene[,i] <- strp(tx2gene[,i])
```

The following three functions provide a table with the OFDR control
described above. To repeat, the set of genes passing screening should
not have more than 5% of either genes which have no DTU or genes which
contain a transcript with an adjusted p-value less than 5% which do
not participate in DTU.

```{r}
stageRObj <- stageRTx(pScreen=pScreen, pConfirmation=pConfirmation,
                      pScreenAdjusted=TRUE, tx2gene=tx2gene)
stageRObj <- stageWiseAdjustment(object=stageRObj, method="dtu", alpha=0.05)
suppressWarnings({
  dex.padj <- getAdjustedPValues(stageRObj, order=FALSE, onlySignificantGenes=TRUE)
})
head(dex.padj)
```

## SUPPA2

*SUPPA2* is a command-line software package written in Python
which also takes as input *Salmon* quantification, and so for
completeness we also show example commands and evaluated its
performance on the simulated data (cite). *SUPPA2* offers a number of
distinct features, including the ability to translate from *Salmon*
transcript-level quantifications to individual splicing events, which
are cataloged using a specific vocabulary described in the software
usage guide: <https://github.com/comprna/SUPPA>. *SUPPA2* additionally
offers differential analysis on the splicing events, which may be more
valuable to investigators than per-transcript, depending on the system
and research goals (similar to the primary exon-level primary use case of
*DEXSeq*). 

Here, as our DTU simulation involved switching between
expressed transcripts without assessing whether they were separated by
one or more splice events, and as the other two Bioconductor methods
for detecting DTU involve transcript-level analysis, we ran *SUPPA2*
in its differential transcript usage mode. We chose to filter on
transcripts with TPM larger than 1; TPM filtering is a command-line
option available during the `diffSplice` step of *SUPPA2* and this
improves the running time. We did not use gene-correction,
as we wanted to apply the aggregation and correction method
`perGeneQValue` from *DEXSeq* to obtain an FDR bounded set of genes
and transcripts as output. We did not perform the stage-wise analysis
of *SUPPA2* output, although this could be done by small modifications
to the above code for either *DRIMSeq* or *DEXSeq*.

We used the following R code to prepare two files containing
TPM estimates for each of the two groups, using the *tximport* object
defined above:

```{r eval=FALSE}
x <- txi$abundance
x[x < 0.01] <- 0 # eliminate very small TPMs
n <- 6 # sample size per group
write.table(x[,1:n], file=paste0("suppa/group1.tpm"), quote=FALSE, sep="\t")
write.table(x[,n + 1:n], file=paste0("suppa/group2.tpm"), quote=FALSE, sep="\t")
```

The *SUPPA2* example code can be found at the software homepage, but
we include here the code used on the 6 vs 6 analysis. The first line
generates a set of isoforms from the GTF file. The second and third
line generate PSI (percent spliced in) for each transcript from files
containing the TPMs for each group. The final line performs the
differential analysis.

```
python suppa.py generateEvents -f ioi -i gencode.v28.annotation.gtf -o suppa/isoforms
python suppa.py psiPerIsoform -g gencode.v28.annotation.gtf \
  -e suppa/group1.tpm -o suppa/group1
python suppa.py psiPerIsoform -g gencode.v28.annotation.gtf \
  -e suppa/group2.tpm -o suppa/group2
python suppa.py diffSplice -m empirical -th 1 -i suppa/isoforms.ioi \
  -p suppa/group1_isoform.psi suppa/group2_isoform.psi \
  -e suppa/group1.tpm suppa/group2.tpm -o suppa/diff_empirical
```

We imported the analysis results into R:

```{r eval=FALSE}
suppa <- read.delim("suppa/diff_empirical.dpsi")
names(suppa) <- c("txp.gene","dpsi","pval")
suppa$gene <- sub(";.*", "", suppa$txp.gene)
suppa$txp <- sub(".*;", "", suppa$txp.gene)
suppa <- suppa[!is.nan(suppa$dpsi),]
```

The following line was used to compute transcript-level adjusted
p-values. We noticed that *SUPPA2* had a large gain in sensitivity,
while still controlling its FDR, if the set of transcripts examined
were limited to those that passed the *DRIMSeq* filtering steps
above. Therefore, before running any multiple test correction steps,
we filtered to this subset of transcripts.

```{r eval=FALSE}
suppa <- suppa[match(res.txp$feature_id, suppa$txp),]
suppa$padj <- p.adjust(suppa$pval, method="BH")
```

We generated per-gene adjusted p-values, using *perGeneQValue* from *DEXSeq*:

```{r eval=FALSE}
library(DEXSeq)
suppa.dxr <- as(DataFrame(groupID=suppa$gene,
                          pvalue=suppa$pval,
                          padj=rep(1, nrow(suppa))), "DEXSeqResults")
qval <- perGeneQValue(suppa.dxr)
suppa.g <- data.frame(gene=names(qval), qval=qval)
```

# Evaluation of methods for DTU

We begin the evaluation by noting that the methods did not call many
of the DGE genes as DTU. The object `dge.genes` contains the names of
all the genes in which all the isoforms were differentially expressed
by an equal amount (so not DTU). *SUPPA2* output is not included in
the workflow, but it only reported one of the DGE genes as DTU out of
851 with an adjusted p-value less than 0.05. 

The number of DGE called for *DRIMSeq*:

```{r}
res$dge <- res$gene_id %in% dge.genes
with(res, table(sig=adj_pvalue < .05, dge))
```

The number of DGE called for *DEXSeq*:

```{r}
dxr.g$dge <- dxr.g$gene %in% dge.genes
with(dxr.g, table(sig=qval < .05, dge))
```

```{r dtu-gene, out.width="75%", echo=FALSE, fig.cap="Gene-level screening for DTU. True positive rate (y-axis) over false discovery rate (x-axis) for DEXSeq, DRIMSeq, and SUPPA2. The four panels shown are for per-group sample sizes: (A) 3, (B) 6, (C) 9, (D) 12. Circles indicate thresholds of 1\\%, 5\\% and 10\\% nominal FDR, which are filled if the observed value is less than the target (dashed vertical lines)."}
knitr::include_graphics("figs/dtu_gene.jpg")
```

The *iCOBRA* package was used to construct plots to assess the true
positive rate over the false discovery rate at three nominal FDR
thresholds: 1%, 5%, and 10% (cite).  The code for evaluating all
methods and constructing the *iCOBRA* plots is included in the
repository at the following
link: <https://github.com/mikelove/swimdown>
Above we showed an analysis for a comparison of 6 vs 6 samples.
As we were interested in the performance at various sample sizes, we
performed the entire analysis for *DRIMSeq*, *DEXSeq*, and *SUPPA2* at
per-group sample sizes of 3,6,9, and 12. 

At the gene-level, in terms of controlling 
the nominal FDR, *SUPPA2* always controlled its FDR, even for the
smallest sample size, *DEXSeq* controlled except for the 1% threshold
in the smallest case, and *DRIMSeq* exceeded its FDR but approached
the target for larger sample sizes (Figure
\@ref(fig:dtu-gene)). Exceeding the nominal level by a small amount
should be taken with sensitivity in consideration as well.
For example, for the 6 vs 6 comparison, *DRIMSeq* had observed FDR of 12%
at nominal 10%, meaning that for every 100 genes reported as
containing DTU, the method reported 2 extra genes more than its
target. *DRIMSeq* and *DEXSeq* were the most sensitive methods in
recovering gene-level DTU in this simulation.

We assessed the overall false discovery rate (OFDR) procedure
implemented with *stageR* using gene- and transcript-level p-values
from *DRIMSeq* and *DEXSeq*. For *DRIMSeq*, we assessed whether
raising the p-values for transcripts with small difference in
proportion helped to recover OFDR control. *DEXSeq* input to *stageR*
tended to stay within the OFDR bound, and the observed OFDR for *DRIMSeq* with
difference-in-proportion filtering lowered to less than 10% as the sample
size increased (Figure \@ref(fig:dtu-ofdr)). Without the filtering,
the observed OFDR for *DRIMSeq* was otherwise around 20-25%.

```{r dtu-ofdr, out.width="50%", echo=FALSE, fig.cap="Number of true positives and observed OFDR using stageR for 5\\% target. Each method is drawn as a line, and the numbers to the right of the points indicate the per-group sample size. Adjusted p-values for a nominal 5\\% OFDR (dashed vertical line) were generated for DEXSeq and DRIMSeq (with and without post-hoc filtering) from gene- and transcript-level p-values using the stageR framework for stage-wise testing."}
knitr::include_graphics("figs/ofdr.pdf")
```

Finally, we assessed the normal false discovery rate at the
transcript-level without using stage-wise testing for all three
methods (including post-hoc filtering option for *DRIMSeq*), again
using *iCOBRA*. 
This analysis looked across the transcript-level adjusted p-values for DTU
without using the information associating transcripts to gene. *SUPPA2* again
tended to control its FDR, as did *DEXSeq* (Figure \@ref(fig:dtu-txp)). 
*DRIMSeq* with difference-in-proportion filtering approached the target FDR sample
size increased for the 5% and 10% targets, while without filtering,
the observed FDR was always higher than the target.
While we performed this last evaluation on the independently adjusted
p-values from the transcript-level, we recommend instead to use the
stage-wise framework and adjusted p-values provided by the *stageR*
method, assessed in Figure \@ref(fig:dtu-ofdr).

```{r dtu-txp, out.width="75%", echo=FALSE, fig.cap="Transcript-level DTU analysis without stage-wise testing. True positive rate (y-axis) over false discovery rate (x-axis) for DEXSeq, DRIMSeq (with and without post-hoc filtering) and SUPPA2. The four panels shown are for per-group sample sizes: (A) 3, (B) 6, (C) 9, (D) 12. Circles indicate thresholds of 1\\%, 5\\% and 10\\% nominal FDR."}
knitr::include_graphics("figs/dtu_txp.jpg")
```

In Table \@ref(tab:timing-dtu) we include the timing for each method at
various sample sizes. Timing includes only the `diffSplice` step of
*SUPPA2* (the other steps take less than a minute). For *DRIMSeq* and
*DEXSeq*, we include the timing of the estimation steps (importing
counts with *tximport* and filtering takes only a few seconds).

TODO: check why 18 minutes for DRIMSeq three times?

: (\#tab:timing-dtu) Timing of methods for DTU in hours:minutes by per-group sample size.

| Method | n=3 | n=6 | n=9 | n=12 |
| --- | --- | --- | --- | --- | 
| *DRIMSeq* | 0:15 | 0:15 | 0:18 | 0:18 |
| *DEXSeq*  | 0:01 | 0:02 | 0:04 | 0:07 |
| *SUPPA2*  | 0:16 | 1:18 | 3:48 | 5:33 |

# DTU analysis complements DGE analysis

## DGE analysis with DESeq2

In the final section of the workflow containing live code examples, we
demonstrate how differential transcript usage, summarized to the
gene-level, can be visualized with respect to differential gene
expression analysis results. We use *tximport* and summarize counts to
the gene level and compute an average transcript length offset for
count-based methods (cite). We will then show code for using *DESeq2*
and *edgeR* to assess differential gene expression. Because we have
simulated the genes according to three different categories, we can
color the final plot by the true simulated state of the genes. We note
that, we will pair *DEXSeq* with *DESeq2* results in the following
plot, and *DRIMSeq* with *edgeR* results, although this pairing is
somewhat arbitrary, and any DTU method can reasonably be paired with
any DGE method.

The following line of code is unevaluated, but was used to generate an
object `txi.g` which contains the gene-level counts, abundances and
average transcript lengths.

```{r eval=FALSE}
txi.g <- tximport(files, type="salmon", tx2gene=txdf[,2:1])
``` 

For the workflow, we load the `txi.g` object which is saved in a file
`salmon_gene_txi.rda`. We then load the *DESeq2* package and build a
*DESeqDataSet* from `txi.g`, providing also the sample information and
a design formula.

```{r}
load("salmon_gene_txi.rda")
library(DESeq2)
dds <- DESeqDataSetFromTximport(txi.g, samps, ~condition)
```

The following two lines of code run the *DESeq2* analysis (cite).

```{r message=FALSE}
dds <- DESeq(dds)
dres <- DESeq2::results(dds)
```

We can confirm that most of the DTU genes are not included in the
significant results (although some are).

```{r}
length(dtu.genes)
table(rownames(dres)[which(dres$padj < .05)] %in% dtu.genes)
```

Because we happen to know the true status of each of the genes, we can
make a scatterplot of the results, coloring the genes by their status
(whether DGE, DTE, or DTU). 

```{r}
all(dxr.g$gene %in% rownames(dres))
dres <- dres[dxr.g$gene,]
# we can only color because we simulated...
col <- rep(8, nrow(dres))
col[rownames(dres) %in% dge.genes] <- 1
col[rownames(dres) %in% dte.genes] <- 2
col[rownames(dres) %in% dtu.genes] <- 3
```

Figure \@ref(fig:tuge-plot) displays the evidence for differential
transcript usage over that for differential gene expression. We can
see that the DTU genes cluster on the y-axis (mostly not captured
in the DGE analysis), and the DGE genes cluster on the x-axis (mostly
not captured in the DTU analysis). The DTE genes fall in the middle,
as all of them represent DGE, and some of them additionally represent
DTU (if the gene had other expressed transcripts). Because *DEXSeq*
outputs an adjusted p-value of 0 for some of the genes, we set these
instead to a jittered value around $10^{-20}$, so that their number and
location on the x-axis could be visualized. These jittered values
should only be used for visualization.

```{r tuge-plot, dev="png", out.width="50%", fig.cap="Transcript usage over gene expression plot. Each point represents a gene, and plotted are -log10 adjusted p-values for DEXSeq's test of differntial transcript usage (y-axis) and DESeq2's test of differential gene expression (x-axis). Because we simulated the data we can color the genes according to their true category."}
bigpar()
cap.padj <- pmin(-log10(dres$padj), 100)
# this vector only used for plotting
jitter.padj <- -log10(dxr.g$qval + 1e-20)
jp.idx <- jitter.padj == 20
jitter.padj[jp.idx] <- rnorm(sum(jp.idx),20,.25)
plot(cap.padj, jitter.padj, col=col,
     xlab="Gene expression",
     ylab="Transcript usage")
legend("topright",
       c("DGE","DTE","DTU","null"),
       col=c(1:3,8), pch=20, bty="n")
```

## DGE analysis with edgeR

We can repeat the same analysis using *edgeR* as the inference engine
(cite). The following code incorporates the average transcript length
matrix as an offset for an *edgeR* analysis.

```{r message=FALSE}
library(edgeR)
cts.g <- txi.g$counts
normMat <- txi.g$length
normMat <- normMat / exp(rowMeans(log(normMat)))
o <- log(calcNormFactors(cts.g/normMat)) + log(colSums(cts.g/normMat))
y <- DGEList(cts.g)
y <- scaleOffset(y, t(t(log(normMat)) + o))
keep <- filterByExpr(y)
y <- y[keep,]
```

The basic *edgeR* model fitting and results extraction can be
accomplished with the following lines. 

```{r}
y <- estimateDisp(y, design_full)
fit <- glmFit(y, design_full)
lrt <- glmLRT(fit)
tt <- topTags(lrt, n=nrow(y), sort="none")[[1]]
```

We confirm that most of the DTU genes were not reported as DGE:

```{r}
table(rownames(tt)[which(tt$FDR < .05)] %in% dtu.genes)
```

Again, we can color the genes by their true status in the simulation:

```{r}
common <- intersect(res$gene_id, rownames(tt))
tt <- tt[common,]
res.sub <- res[match(common, res$gene_id),]
# we can only color because we simulated...
col <- rep(8, nrow(tt))
col[rownames(tt) %in% dge.genes] <- 1
col[rownames(tt) %in% dte.genes] <- 2
col[rownames(tt) %in% dtu.genes] <- 3
```

Figure \@ref(fig:tuge-drim-edger) displays the evidence for
differential transcript usage over that for differential gene
expression, now using *DRIMSeq* and *edgeR*. One obvious contrast with
Figure \@ref(fig:tuge-plot) is that *DRIMSeq* outputs lower non-zero
adjusted p-values than *DEXSeq* does, where *DEXSeq* instead output 0
for many genes. The plots look more similar when zooming in to the
*DRIMSeq* axis, as can be seen in Figure \@ref(fig:tuge-drim-zoom).

```{r tuge-drim-edger, dev="png", out.width="50%", fig.cap="Transcript usage over gene expression plot, as previously, but for DRIMSeq and edgeR."}
bigpar()
plot(-log10(tt$FDR), -log10(res.sub$adj_pvalue), col=col,
     xlab="Gene expression",
     ylab="Transcript usage")
legend("topright",
       c("DGE","DTE","DTU","null"),
       col=c(1:3,8), pch=20, bty="n")
```

```{r tuge-drim-zoom, dev="png", out.width="50%", fig.cap="Transcript usage over gene expression plot, zooming in on the DRIMSeq adjusted p-values."}
bigpar()
plot(-log10(tt$FDR), -log10(res.sub$adj_pvalue), col=col,
     xlab="Gene expression",
     ylab="Transcript usage", ylim=c(0,20))
legend("topright",
       c("DGE","DTE","DTU","null"),
       col=c(1:3,8), pch=20, bty="n")
```

# Evaluation of methods for DGE

```{r dge, out.width="75%", echo=FALSE, fig.cap="DGE foo bar"}
knitr::include_graphics("figs/dge.jpg")
```
We additionally assessed Bioconductor and R packages for differential
gene expression, to determine true positive rate and control of false
discovery rate. In this analysis, the simulated "DTE" genes (where a single
transcript was chosen to be differentially expressed) should count for
differential gene expression, while the simulated "DTU" genes should
not, as the expression remains constant. 

: (\#tab:timing-dge) Timing of methods for DGE rounded to the
  minute by per-group sample size. Timing includes data import and
  summarization to gene-level quantities.

| Method | n=3 | n=6 | n=9 | n=12 |
| ---------- | --- | --- | --- | --- | 
| *DESeq2*   | <1 | <1 | <1 | <1 |
| *EBSeq*    | 1 | 2 | 2 | 3 |
| *edgeR*    | <1 | <1 | <1 | <1 |
| *edgeR-QL* | <1 | <1 | <1 | <1 |
| *limma*    | <1 | <1 | <1 | <1 |
| *SAMSeq*   | <1 | <1 | <1 | <1 |
| *sleuth*   | 2 | 4 | 5 | 7 |

: (\#tab:timing-dte) Timing of methods for DTE rounded to the nearest
  minute by per-group sample size. Timing includes data import.

| Method | n=3 | n=6 | n=9 | n=12 |
| ---------- | --- | --- | --- | --- | 
| *DESeq2*   | <1 | <1 | <1 | 1 |
| *EBSeq*    | 5 | 11 | 18 | 22 |
| *edgeR*    | <1 | <1 | <1 | <1 |
| *edgeR-QL* | <1 | <1 | <1 | <1 |
| *limma*    | <1 | <1 | <1 | <1 |
| *SAMSeq*   | <1 | <1 | <1 | 1 |
| *sleuth*   | 2 | 2 | 2 | 2 |

# Evaluation of methods for DTE

```{r dte, out.width="75%", echo=FALSE, fig.cap="DTE foo bar"}
knitr::include_graphics("figs/dte.jpg")
```
Finally, we assessed the Bioconductor and R packages for differential
transcript expression. While we believe the separation of differential
transcript usage and differential gene expression described in the
earlier sections of the workflow represent an easily interpretable
approach, some investigators may prefer to assess differential
expression on a per-transcript basis. For this assessment, all of the
simulated non-null transcripts count as DTE, whether from the
simulated "DGE", "DTE", or "DTU" genes.

# Discussion 

This section is only required if the paper includes novel data or analyses, and should be written in the same style as a traditional discussion section.
Please include a brief discussion of allowances made (if any) for controlling bias or unwanted sources of variability, and the limitations of any novel datasets.

# Session information

The following provides the session information used when compiling
this document. 

```{r}
devtools::session_info()
```

# Data availability 

Please add details of where any datasets that are mentioned in the paper, and that have not have not previously been formally published, can be found.  If previously published datasets are mentioned, these should be cited in the references, as per usual scholarly conventions.

# Software availability

This section will be generated by the Editorial Office before publication. Authors are asked to provide some initial information to assist the Editorial Office, as detailed below.

1. All software used in this workflow is available as part of Bioconductor version 3.7.
2. Source: https://github.com/mikelove/rnaseqDTU
3. Link to source code as at time of publication (*F1000Research* TO GENERATE)
4. Link to archived source code as at time of publication (*F1000Research* TO GENERATE)
5. License: Artistic-2.0

# Author information

In order to give appropriate credit to each author of an article, the individual contributions of each author to the manuscript should be detailed in this section. We recommend using author initials and then stating briefly how they contributed.

# Competing interests

No competing interests were disclosed.

# Grant information

Please state who funded the work discussed in this article, whether it is your employer, a grant funder etc. Please do not list funding that you have that is not relevant to this specific piece of research. For each funder, please state the funders name, the grant number where applicable, and the individual to whom the grant was assigned. If your work was not funded by any grants, please include the line: 'The author(s) declared that no grants were involved in supporting this work.'

# Acknowledgments

This section should acknowledge anyone who contributed to the research or the article but who does not qualify as an author based on the criteria provided earlier (e.g. someone or an organization that provided writing assistance). Please state how they contributed; authors should obtain permission to acknowledge from all those mentioned in the Acknowledgments section.

# References

